DDInter1152 DDInter1652
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incid
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Mephenytoin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Mephenytoin {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Mephenytoin may lead to a major life threatening interaction when taken with Teriflunomide
Mephenytoin may lead to a major life threatening interaction when taken with Fluconazole